Efficacy of Cognitive Behavioral Therapy for Anxiety‑Related Disorders: A Meta‑Analysis of Recent Literature
Metadata
Show full item recordEditorial
Springer
Materia
Anxiety Anxiety disorders Cognitive behavioral therapy Meta-analysis Posttraumatic stress disorder Randomized controlled trials
Date
2022-12-19Referencia bibliográfica
Bhattacharya, S... [et al.]. Efficacy of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Meta-Analysis of Recent Literature. Curr Psychiatry Rep 25, 19–30 (2023). [https://doi.org/10.1007/s11920-022-01402-8]
Sponsorship
Alexander von Humboldt Foundation; United States Department of Health & Human Services National Institutes of Health (NIH) - USA R01AT007257 United States Department of Health & Human Services National Institutes of Health (NIH) - USA NIH National Institute of Mental Health (NIMH) R01MH099021 U01MH108168; James S. McDonnell Foundation 21st Century Science Initiative in Understanding Human Cognition - Special Initiative; Projekt DEALAbstract
Purpose of Review Effective treatment of anxiety-related disorders is crucial, considering the prevalence of such disorders
and their association with poor psychosocial functioning. To evaluate the most recent evidence on the efficacy of cognitive
behavioral therapy (CBT) for anxiety-related disorders in adults, we conducted a meta-analysis of randomized placebocontrolled
trials published since 2017.
Recent Findings Ten studies with a total of 1250 participants met the inclusion criteria. Seven of these studies examined
PTSD. The findings demonstrated small placebo-controlled effects of CBT on target disorder symptoms (Hedges’ g = 0.24,
p < 0.05) and depression (Hedges’ g = 0.15, p = n.s). When examining only PTSD studies, effects were reduced (Hedges’
g = 0.14, p < 0.05). Heterogeneity in most analyses was very low, and no publication bias was found.
Summary Effect sizes from placebo-controlled trials from the past 5 years appear to be smaller than those in prior metaanalyses.
The findings are largely driven by research on PTSD, with few placebo-controlled trials of other anxiety-related
disorders published since 2017.